Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8O3.H2O |
| Molecular Weight | 194.184 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC(=O)OC2=C1C=CC(O)=C2
InChI
InChIKey=HRFJWEHVFMYQSS-UHFFFAOYSA-N
InChI=1S/C10H8O3.H2O/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9;/h2-5,11H,1H3;1H2
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Hymecromone (4-methylumbelliferone) is already approved drug in Europe and Asia where it is used to treat biliary spasm. It is used as choleretic and antispasmodic drugs and as a standard for the fluorometric determination of enzyme activity. The concomitant administration of Hymecromone with products, containing metoclopramide, leads to mutual decrease of their action. Due to a danger of diarrhea with subsequent hypokalemia, Hymecromone should be applied with caution to patients on cardiac glycosides therapy (in these cases the sensitivity to them is increased). Hymecromone can be administered simultaneously with otherspasmolytics and analgesics. Very rare allergic reactions, itching, erythema, rashes; diarrhea which normally disappears by reduction of dose or discontinuance of therapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of ATP on regulation of galactosyltransferase-I activity responsible for synthesis of the linkage region between the core protein and glycosaminoglycan chains of proteoglycans. | 2001 |
|
| New lanthanide complexes of 4-methyl-7-hydroxycoumarin and their pharmacological activity. | 2001 Apr |
|
| Cloning and characterization of a bacterial cell-bound type B carboxylesterase from Bacillus sp. BP-7. | 2001 Apr |
|
| Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. | 2001 Dec |
|
| [Odeston in treatment of chronic diseases of hepatobiliary system]. | 2001 Feb |
|
| Molecular cloning and expression of an alpha-mannosidase gene in Mycobacterium tuberculosis. | 2001 Jan |
|
| Thermodynamic analysis of saccharide binding to snake gourd (Trichosanthes anguina) seed lectin. Fluorescence and absorption spectroscopic studies. | 2001 Jan |
|
| A convenient fluorometric method for the detection of extracellular N-acetylglucosaminidase production by filamentous fungi. | 2001 Jan |
|
| Extracellular enzyme activities during slow sand filtration in a water recharge plant. | 2001 Jul |
|
| Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule. | 2001 Jun 22 |
|
| Improved method for the fluorimetric detection of beta-D-galactosidase in water. | 2001 Mar |
|
| Synthesis, physicochemical characterization, and cytotoxic screening of new zirconium complexes with coumarin derivatives. | 2001 May |
|
| High beta-galactosidase and ganglioside GM1 levels in the human parotid gland. | 2001 Nov |
|
| A fluorogenic assay using pressure-driven flow on a microchip. | 2001 Oct |
|
| [Ground and first singlet excited dissociation constants of 4-methylumbelliferone: application for indirect spectrofluorimetry of nitriles and nitrosamines]. | 2001 Sep |
|
| An alternative approach for enumeration of Escherichia coli in foods. | 2001 Sep 1 |
|
| Development of an enzyme assay for rapid assessment of Escherichia coli in seawaters. | 2002 |
|
| Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme. | 2002 Apr |
|
| Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus. | 2002 Aug 16 |
|
| UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. | 2002 Feb 1 |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of drugs. I: studies by in vivo constant infusion. | 2002 May |
|
| The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. | 2002 May 20 |
|
| Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. | 2002 Nov |
|
| Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. | 2002 Sep |
|
| [Effect of vegetotropic pharmacologic preparations of the motor-evacuatory function of the gallbladder in patients with chronic biliary tract pathology]. | 2003 |
|
| Polar organic solvent added to an aqueous solution changes hydrolytic property of lipase. | 2003 Aug |
|
| Inhibition of rat liver sulfotransferases SULT1A1 and SULT2A1 and glucuronosyltransferase by dietary flavonoids. | 2003 Dec |
|
| Verapamil regulates activity and mRNA-expression of human beta-glucuronidase in HepG2 cells. | 2003 Dec |
|
| Kinetic studies on the hydrolysis of N-acetylated and N-deacetylated derivatives of 4-methylumbelliferyl chitobioside by the family 18 chitinases ChiA and ChiB from Serratia marcescens. | 2003 Feb |
|
| HNK-1-Reactive oligosaccharide, sulfate-O-3GlcAbeta1-4Xylbeta1-MU, synthesized by cultured human colorectal cancer cells. | 2003 Jan |
|
| A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside. | 2003 Jan 20 |
|
| Development of fluorescence-based selective assays for serine/threonine and tyrosine phosphatases. | 2003 Jun |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. | 2003 Nov |
|
| A nonradioactive 96-well plate assay for screening of trans-sialidase activity. | 2003 Nov 15 |
|
| Structural requirements of hydroxylated coumarins for in vitro anti-Helicobacter pylori activity. | 2003 Sep-Oct |
|
| DNA damage in healthy term neonate. | 2004 Apr |
|
| Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. | 2004 Apr |
|
| Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. | 2004 Jan 30 |
|
| Stability of the complexes of some lanthanides with coumarin derivatives. I. Cerium(III)-4-methyl-7-hydroxycoumarin. | 2004 Mar |
|
| Synthesis and biological activity of substituted 2,4,6-s-triazines. | 2004 Mar |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004 Mar-Apr |
Sample Use Guides
1 tablet 3 times daily during basic meals. The tablets are administered unchewed with a liquid.
Route of Administration:
Oral
4-Methylumbelliferone (4-MU/HYMECROMONE) inhibits hyaluronan synthesis and retards cancer spreading in experimental animals through mechanisms not fully understood. These mechanisms were studied in A2058 melanoma cells, MCF-7 and MDA-MB-361 breast, SKOV-3 ovarian and UT-SCC118 squamous carcinoma cells by analysing hyaluronan synthesis, UDP-glucuronic acid (UDP-GlcUA) content, and hyaluronan synthase (HAS) mRNA levels. The maximal inhibition in hyaluronan synthesis ranged 22-80% in the cell lines tested. Active glucuronidation of 4-MU produced large quantities of 4-MU-glucuronide, depleting the cellular UDP-GlcUA pool. The maximal reduction varied between 38 and 95%. 4-MU also downregulated HAS mRNA levels: HAS3 was 84-60% lower in MDA-MB-361, A2058 and SKOV-3 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:53:55 GMT 2023
by
admin
on
Sat Dec 16 07:53:55 GMT 2023
|
| Record UNII |
ORG176G874
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
103764-33-6
Created by
admin on Sat Dec 16 07:53:55 GMT 2023 , Edited by admin on Sat Dec 16 07:53:55 GMT 2023
|
PRIMARY | |||
|
ORG176G874
Created by
admin on Sat Dec 16 07:53:55 GMT 2023 , Edited by admin on Sat Dec 16 07:53:55 GMT 2023
|
PRIMARY | |||
|
DTXSID1046976
Created by
admin on Sat Dec 16 07:53:55 GMT 2023 , Edited by admin on Sat Dec 16 07:53:55 GMT 2023
|
PRIMARY | |||
|
60196415
Created by
admin on Sat Dec 16 07:53:55 GMT 2023 , Edited by admin on Sat Dec 16 07:53:55 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
